These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 8333874)
1. Models for the A- and B-receptor-bound conformations of CCK-8. Nikiforovich GV; Hruby VJ Biochem Biophys Res Commun; 1993 Jul; 194(1):9-16. PubMed ID: 8333874 [TBL] [Abstract][Full Text] [Related]
2. The use of topographical constraints in receptor mapping: investigation of the topographical requirements of the tryptophan 30 residue for receptor binding of Asp-Tyr-D-Phe-Gly-Trp-(N-Me)Nle-Asp-Phe-NH2 (SNF 9007), a cholecystokinin (26-33) analogue that binds to both CCK-B and delta-opioid receptors. Boteju LW; Nikiforovich GV; Haskell-Luevano C; Fang SN; Zalewska T; Stropova D; Yamamura HI; Hruby VJ J Med Chem; 1996 Sep; 39(20):4120-4. PubMed ID: 8831778 [TBL] [Abstract][Full Text] [Related]
3. Further evidence for a C-terminal structural motif in CCK2 receptor active peptide hormones. Stone SR; Giragossian C; Mierke DF; Jackson GE Peptides; 2007 Nov; 28(11):2211-22. PubMed ID: 17950490 [TBL] [Abstract][Full Text] [Related]
5. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies. Béhé M; Behr TM Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727 [TBL] [Abstract][Full Text] [Related]
6. Mapping of ligand binding sites of the cholecystokinin-B/gastrin receptor with lipo-gastrin peptides and molecular modeling. Lutz J; Romano-Götsch R; Escrieut C; Fourmy D; Mathä B; Müller G; Kessler H; Moroder L Biopolymers; 1997 Jun; 41(7):799-817. PubMed ID: 9128441 [TBL] [Abstract][Full Text] [Related]
7. Conformationally constrained CCK8 analogues obtained from a rationally designed peptide library as ligands for cholecystokinin type B receptor. De Luca S; Saviano M; Della Moglie R; Digilio G; Bracco C; Aloj L; Tarallo L; Pedone C; Morelli G ChemMedChem; 2006 Sep; 1(9):997-1006. PubMed ID: 16915602 [TBL] [Abstract][Full Text] [Related]
8. Conformational analysis of CCK-B agonists using 1H-NMR and restrained molecular dynamics: comparison of biologically active Boc-Trp-(N-Me) Nle-Asp-Phe-NH2 and inactive Boc-Trp-(N-Me)Phe-Asp-Phe-NH2. Goudreau N; Weng JH; Roques BP Biopolymers; 1994 Feb; 34(2):155-69. PubMed ID: 8142585 [TBL] [Abstract][Full Text] [Related]
9. Ac-[3- and 4-alkylthioproline31]-CCK4 analogs: synthesis and implications for the CCK-B receptor-bound conformation. Kolodziej SA; Nikiforovich GV; Skeean R; Lignon MF; Martinez J; Marshall GR J Med Chem; 1995 Jan; 38(1):137-49. PubMed ID: 7837225 [TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological activity of CCK heptapeptide analogues. Effects of conformational constraints and standard modifications on receptor subtype selectivity, functional activity in vitro, and appetite suppression in vivo. Holladay MW; Bennett MJ; Tufano MD; Lin CW; Asin KE; Witte DG; Miller TR; Bianchi BR; Nikkel AL; Bednarz L J Med Chem; 1992 Aug; 35(16):2919-28. PubMed ID: 1501220 [TBL] [Abstract][Full Text] [Related]
11. Conformational analysis of possible biologically active (receptor-bound) conformations of peptides derived from cholecystokinin, cerulein and little gastrin and the opiate peptide, Met-enkephalin. Pincus MR; Murphy RB; Carty RP; Chen J; Shah D; Scheraga HA Peptides; 1988; 9 Suppl 1():145-52. PubMed ID: 2856638 [TBL] [Abstract][Full Text] [Related]
12. Cholecystokinin-B/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential. Behr TM; Béhé M; Angerstein C; Gratz S; Mach R; Hagemann L; Jenner N; Stiehler M; Frank-Raue K; Raue F; Becker W Clin Cancer Res; 1999 Oct; 5(10 Suppl):3124s-3138s. PubMed ID: 10541353 [TBL] [Abstract][Full Text] [Related]
13. Peptide/benzodiazepine hybrids as ligands of CCK(A) and CCK(B) receptors. Escherich A; Lutz J; Escrieut C; Fourmy D; van Neuren AS; Müller G; Schafferhans A; Klebe G; Moroder L Biopolymers; 2000-2001; 56(2):55-76. PubMed ID: 11592053 [TBL] [Abstract][Full Text] [Related]
14. Structure-based design of new constrained cyclic agonists of the cholecystokinin CCK-B receptor. Blommaert AG; Dhôtel H; Ducos B; Durieux C; Goudreau N; Bado A; Garbay C; Roques BP J Med Chem; 1997 Feb; 40(5):647-58. PubMed ID: 9057851 [TBL] [Abstract][Full Text] [Related]
15. NMR evidence for different conformations of the bioactive region of rat CCK-8 and CCK-58. Keire DA; Solomon TE; Reeve JR Biochem Biophys Res Commun; 2002 May; 293(3):1014-20. PubMed ID: 12051761 [TBL] [Abstract][Full Text] [Related]
16. Synthesis, biological evaluation, and quantitative receptor docking simulations of 2-[(acylamino)ethyl]-1,4-benzodiazepines as novel tifluadom-like ligands with high affinity and selectivity for kappa-opioid receptors. Cappelli A; Anzini M; Vomero S; Menziani MC; De Benedetti PG; Sbacchi M; Clarke GD; Mennuni L J Med Chem; 1996 Feb; 39(4):860-72. PubMed ID: 8632410 [TBL] [Abstract][Full Text] [Related]
17. Binding of cholecystokinin-8 (CCK-8) peptide derivatives to CCKA and CCKB receptors. Schäfer U; Harhammer R; Boomgaarden M; Sohr R; Ott T; Henklein P; Repke H J Neurochem; 1994 Apr; 62(4):1426-31. PubMed ID: 8133271 [TBL] [Abstract][Full Text] [Related]
18. Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors. Reubi JC; Schaer JC; Waser B Cancer Res; 1997 Apr; 57(7):1377-86. PubMed ID: 9102227 [TBL] [Abstract][Full Text] [Related]